Clinical trial of Carperitide and Torasemide (HANSAM therapy) in cardiac surgery (HANSAM trial).

Clinical trial of Carperitide and Torasemide (HANSAM therapy) in cardiac surgery (HANSAM trial). - HANSAM trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013654

Enrollment

100

Registered

2014-04-07

Start date

2014-04-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

valve disease, thoracic aortic aneurysm, angina, myocardial infarction et.al.

Interventions

intra-and perioperative administration of carperitide and postoperative administration of torvaptan intra-and perioperative administration of carperitide and postoperative administration of frosemide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient undergoing cardiac surgery patients from whom informed consent was obtained

Exclusion criteria

Exclusion criteria: cardiogenic shock hemodiaisis Doctor's decision not to register to this regimen

Design outcomes

Primary

Measure	Time frame
Urine volume	—

Secondary

Measure	Time frame
1) BNP 3) renin activity, angiotensin-II, aldsterone 4) CK-MB, Tp-I, H-FABP 5) serum creatinine (sCr) 6) mortality, complication 7) postoperative death (early, late) 8) MACCE	—

Countries

Japan

Contacts

Public ContactAkira Sezai

Nihon University School of Medicine Department of Cardiovascular Surgery

asezai.med@gmail.com03-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026